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Summary. Unravelling the structure, function and
molecular interactions of factor VIII (FVIII) through-
out its life cycle from biosynthesis to clearance has
advanced our understanding of the molecular mech-
anisms of haemophilia and the development of
effective treatment strategies including recombinant
replacement therapy. These insights are now influ-
encing bioengineering strategies toward novel thera-
peutics. Whereas available molecular models and
crystal structures have helped elucidate the structure
and function of the A and C domains of FVIII, these
models have not included detailed structural infor-
mation of the B domain. Therefore, insights into the
role of the FVIII B domain have come primarily from
expression studies in heterologous systems, biochem-
ical studies on bioengineered FVIII variants and
clinical studies with B domain-deleted FVIII. This
manuscript reviews the available data on the potential
functional roles of the FVIII B domain. A detailed
literature search was performed, and the data
extracted were qualitatively summarized. Intriguing
emerging evidence suggests that the FVIII B domain is
involved in intracellular interactions that regulate
quality control and secretion, as well as potential
regulatory roles within plasma during activation,
platelet binding, inactivation and clearance.
Keywords: B domain, blood coagulation factors,
factor VIII, haemophilia A, protein engineering,
recombinant proteins
Introduction
Factor VIII (FVIII) is a large, complex, essential
glycoprotein coagulation factor with a still incom-
pletely understood life cycle. The primary structure
of FVIII was identified only in the early 1980s, when
the protein was purified to complete homogeneity,
and its cDNA cloned [1,2]. While considerable and
steady progress has subsequently been made on
unravelling the structure, function and molecular
interactions of FVIII throughout its life cycle from
biosynthesis to clearance, a complete picture has still
not emerged [3–5]. Activated FVIII (FVIIIa) assem-
bles within the tenase complex on a phospholipid
surface, such as activated platelets, where it functions
as a non-enzymatic cofactor for factor IXa (FIXa) in
the activation of factor X (FX). This cofactor
function is similar to that of its homologous cofactor,
activated factor Va (FVa), which assembles within
the prothrombinase complex, exerting cofactor
function for FXa for the activation of prothrombin.
The FVIII gene comprises 26 exons, which encode
a polypeptide chain for a signal peptide of 19 amino
acids and a mature protein of 2332 amino acids [4].
FVIII is synthesized as an inactive single chain with
the discrete domain structure of A1-a1-A2-a2-B-a3-
A3-C1-C2 (Fig. 1). Domains a1, a2 and a3 are acidic
amino acid rich regions between the major structural
domains and contain sulfated tyrosine residues. The
A domains of FVIII share approx. 40% amino acid
identity with each other and to the A domains of FV.
The FVIII C domains in turn also exhibit approx.
40% amino acid identity to each other and to the C
domains of FV and proteins that bind negatively
charged phospholipids, suggesting a role in phos-
pholipid interaction.
Encoded by exon 14, the B domain spans the
sequence from amino acids 741–1648. Several char-
acteristics distinguish the B domain. One unusual
feature is the encoding of the B domain entirely by a
single very large uninterrupted exon. Unlike other
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portions of the FVIII molecule, the B domain is
without amino acid homology to other known pro-
teins, including the B domain of FV. FVIII does share
with FV the distinctive property of having extensive
glycosylation of B domain asparagine, serine and
threonine residues. The B domain contains 19 of the
potential 25 asparagine (N)-linked glycosylation
attachment sites on the entire FVIII molecule [2].
While the B domain is not directly necessary for
the central procoagulant activity of FVIII [6,7],
more recently it has been shown to play a major
role in the intracellular processing and trafficking
of FVIII. Moreover, there is emerging evidence
that portions of the B domain may have
functional influences throughout the life cycle
of FVIII (Table 1) [8–20]. This review delineates
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Fig. 1. Domain structure and processing of FVIII. Abbreviations: aPC, activated protein C; FVIII, factor VIII; FVIIIa, activated factor VIII.
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the known intracellular functions of the B domain
and its potential roles following secretion into
plasma.
Synthesis and intracellular processing of factor VIII
FVIII is believed to be produced primarily in
hepatocytes and endothelial cells [4,21]. Thus far,
no established or primary cell lines expressing FVIII
have been developed, and consequently evidence on
the extensive post-translational processing and secre-
tion of FVIII has been generated from expression of
the FVIII complementary DNA (cDNA) in transfect-
ed mammalian cells, such as Chinese hamster ovary
(CHO), African green monkey kidney (COS-1),
HeLa, and the human hepatic cell line, SK-HEP1
[13,22]. FVIII is poorly expressed and inefficiently
secreted in these heterologous systems. Expression is
two to three orders of magnitude lower than that
observed with other cDNAs of similar-sized proteins
using similar vectors and methods [23]. This has
stimulated an extensive effort to delineate the traf-
ficking of FVIII through the cellular secretory
machinery and identify the structures and processes
necessary for efficient secretion of functional FVIII
molecules. The B domain has been found to figure
prominently in these processes.
Transcription and translation Reduced FVIII mRNA
accumulation has been observed in several cell lines.
Deletion analysis within FVIII expression vectors
demonstrated that diffuse sequences within the FVIII
coding region have a deleterious effect upon RNA
accumulation [24]. The FVIII cDNA contains a
305 bp transcriptional silencer that dominantly
inhibits its own expression [25]. Shortly after the
cloning and subsequent expression of FVIII, it was
demonstrated that the B domain was dispensable for
its procoagulant activity [6,7]. Removal of the B
domain, the equivalent of approx. 38% of the
primary cDNA sequence, significantly improved the
yield of FVIII [6]. The increased expression resulted
from markedly increased levels of mRNA and
increased translation [26]. However, detailed studies
on the expression of recombinant B domain-deleted
forms of FVIII (BDD-rFVIII) indicated that despite
an increase in mRNA approaching 20-fold, the yield
of secreted BDD-rFVIII was improved by no more
than 2-fold [10]. This suggests a role for the B
domain during other steps within the FVIII biosyn-
thetic pathway.
Quality control system Secretory proteins follow
a path through the cell that leads through the
endoplasmic reticulum (ER) to an endoplasmic
reticulum-Golgi intermediate compartment (ERGIC)
and finally to the Golgi before release into the
plasma. After synthesis the FVIII protein, directed by
the signal peptide, is translocated into the lumen of
the ER, which serves as the major site for the folding
and assembly of secretory proteins as well as integral
membrane proteins. Facilitated by enzymes and
molecular chaperones, newly synthesized proteins
fold and assemble into tertiary structures within the
ER [13]. The molecular chaperones also serve as an
essential part of the ER quality control (QC) system





Enables interaction of factor VIII with chaperone pro-
teins that distinguish properly folded tertiary structure
of proteins; stabilizes folded domains, prevents aggre-
gation
Pipe et al. [13]
Secretion Interacts with cargo-specific sorting receptor complex
that enables endoplasmic reticulum to Golgi transport;
increases secretion efficiency
Moussalli et al. [14]; Cunningham et al.
[15]; Miao et al. [16]; Pipe et al. [18];
Zhang et al. [19]
Plasma
Activation Possibly shields thrombin activation site from pre-
mature proteolysis
Eaton et al. [8]; Meulien et al. [9]; Pitt-
man et al. [10]; Pittman et al. [11]
Platelet binding Decreases the affinity of unactivated factor VIII for
activated platelets, thus preserving circulating factor
VIII
Li and Gabriel [12]
Inactivation Reduces proteolysis by
activated protein
C and factor Xa
Khrenov et al. [20]
Clearance May play a further role in factor VIII quality control
through interaction with asialoglyprotein receptor
Bovenschen et al. [17]
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ensuring export of only properly folded proteins. The
QC system recognizes general structural differences
between native and non-native proteins and prevents
the secretion of non-native proteins that could be
non-functional and antigenic.
Cleavage and glycosylation Upon entering the ER,
the signal peptide is cleaved off to produce the
mature 2332 amino acid FVIII protein. Important
structural post-translational modifications occur
cotranslationally in which a 14-sugar branched chain
is added to the amide nitrogen of consensus aspar-
agine side chains (Figs 1 and 2) [4]. The B domain is
the principal region for this modification, accounting
for more than three-quarters of the potential
25 N-linked glycosylation attachment sites in the
FVIII molecule. These carbohydrate moieties not
only stabilize folded domains but also provide polar
surface groups that prevent aggregation of folding
intermediates and allow newly synthesized polypep-
tide chains to interact with ER chaperones and
enzymes. The B domain carbohydrates appear to be
important for FVIII secretion, since inhibition of
N-linked glycosylation by tunicamycin treatment
dramatically reduces secretion [26].
Chaperone proteins The high mannose-containing
N-linked oligosaccharides of the B domain interact
with two protein chaperones: calnexin, an integral
ER membrane protein, and calreticulin, an ER
luminal protein (Fig. 2). The calnexin/calreticulin
cycle promotes folding of glycoproteins and retains
non-native glycoproteins in the ER until they are
correctly folded [27]. Two of three glucose units are
rapidly trimmed from the 14-subunit oligosaccha-
rides attached to asparagine residues, allowing spe-
cific recognition and binding by calnexin and
calreticulin to the cleaved carbohydrate structure.






















Fig. 2. Intracellular trafficking processes
involving the B domain of FVIII.
Abbreviations: ERGIC, endoplasmic
reticulum Golgi intermediate compartment;
FVIII, factor VIII; LMAN1,
mannose-binding lectin 1; MCFD2,
multiple coagulation factor deficiency
protein 2; QC, quality control.
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When the third glucose unit is enzymatically
removed, FVIII is released from the two chaperone
proteins. If the protein is correctly folded, it can leave
the cycle and exit the ER. Otherwise, the protein
re-enters the cycle or undergoes degradation.
The B domain was shown to be important for
this QC function in a study of CHO cells [13]. The
interaction with both calnexin and calreticulin of a
FVIII fragment lacking most of the B domain (residues
759–1639 deleted) was significantly reduced. More-
over, in the presence of inhibitors of glucose trimming,
the interactions of FVIII with calnexin and calreticulin
were also attenuated, and the secretion of FVIII
inhibited.
Cargo receptor binding After proper folding, FVIII
proceeds toward the Golgi apparatus packaged in
coated vesicles that uncoat and fuse with each other
to form the ERGIC (Fig. 2). A cargo-specific sorting
receptor complex consisting of the transmembrane
protein mannose-binding lectin 1 (LMAN1, also
known as ERGIC-53) and its soluble luminal inter-
action partner, multiple coagulation factor deficiency
protein 2 (MCFD2), are required for this process.
Mutations in LMAN1 or MCFD2 cause combined
deficiency of FV and FVIII [28]. This disorder is
associated with plasma levels of FV and FVIII
ranging from 5% to 30% of normal. In an initial
study of a tetracycline-inducible HeLa cell line, it
was shown that when the cells overexpressed a
mutant ERGIC-53 that was unable to exit the ER,
the secretion of FVIII, as well as FV, was defective,
and that this shuttling of the coagulation factors
appeared to be dependent on post-translational
modification of N-linked oligosaccharides [14].
Subsequent data from the HeLa cell line suggested
that FVIII-specific protein sequences also contribute
to LMAN1 interaction [15]. In both COS-1 and
CHO cells, LMAN1 and MCFD2 interacted specifi-
cally with FVIII, and the B domain was the most
likely site of the interaction [19]. BDD-rFVIII did not
bind to the LMAN1-MCFD2 complex or displayed
markedly reduced binding affinity. In contrast to
earlier studies, this investigation suggested that the
interaction might be independent of the FVIII glyco-
sylation state. Calcium-dependent protein-protein
interactions appeared to play a possible role. Further
studies are required to pinpoint more precisely
elements within the B domain that are important
for cargo receptor binding.
Golgi partial proteolysis Once in the Golgi com-
partment, FVIII is among the many proteins to
undergo intracellular proteolysis (Fig. 2). The ter-
tiary structure of FVIII confers on the B domain
region a particular susceptibility to proteolysis. The
heavy- and light-chain portions of FVIII form a
globular domain, while the connecting B domain
region forms an exposed extended rod-like structure
[29]. Moreover, the middle part and the carboxy-
terminal region of the B domain comprise a motif
(Arg-X-X-Arg) similar to that recognized by intra-
cellular proteases of the subtilisin-like family [4].
Consequently, the FVIII polypeptide is cleaved in the
B domain after residues 1313 and 1648 to generate
the heavy chain of 200 kD (A1-a1-A2-a2-B) in a
metal ion complex with the light chain of 80 kD (a3-
A3-C1-C2). Within the Golgi apparatus, FVIII also
undergoes modification of the N-linked oligosaccha-
rides to complex-type structures, O-linked glycosyl-
ation, and sulfation of specific tyrosine residues.
Secretion efficiency In the absence of the B domain,
secretion still occurs but is generally very inefficient.
Several BDD-rFVIII species with variable amounts of
the B domain deleted have been investigated, such as
FVIIIdes-797-1652 [8], FVIIIdes-771–1666 (FVIII-II,
165 kDa) [30] and FVIIIdes-760–1639 (LA-VIII)
[10]. The only commercially available BDD-rFVIII
protein, moroctocog alfa (ReFacto; Wyeth Phar-
maceuticals, Collegeville, PA, USA), possesses a 14
amino acid B domain sequence linking Ser743 to
Gln1638, joining the A2 and A3 domains. In each
case, the B domain has not been completely deleted,
so that small portions are retained. In transfected
cells, BDD-rFVIII generally exhibits high levels of
mRNA yet the resultant translated proteins are not
fully reflected in the amount of secreted protein
observed, suggesting intracellular interactions are
limiting efficient secretion [10]. The LMAN1/
MCFD2 protein complex appears to interact with
its cargo primarily through interaction with mannose
residues on N-linked oligosaccharides. Thus, BDD-
rFVIII, missing the majority of the N-linked oligo-
saccharides clustered within the B domain, may not
be able to take full advantage of this facilitated
transport pathway. The addition of even a small
portion of native FVIII B domain (optimally 226
amino acids with six N-linked oligosaccharides) to
BDD-rFVIII produced a 5- to 10-fold higher secre-
tion efficiency compared to BDD-rFVIII [16]. These
studies support a central role of the B domain in the
efficient secretion of full-length FVIII.
The B domain is by no means the sole determinant
of efficient FVIII secretion process. For example,
interaction of elements within the FVIII A1 domain
with the protein chaperone BiP in the ER has also
been shown to limit FVIII secretion [31]. The relative
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contribution of various cellular processes may also
depend upon the particular transfected cell line used.
Further research is needed to understand more fully
the interplay of intracellular chaperones and other
intracellular molecules involved in cellular quality
control that act in concert to ensure that only
functional, properly folded FVIII molecules are
secreted.
Fate of factor VIII in circulation
Although the B domain is partially cleaved prior to
secretion in the Golgi, a substantial portion persists
in the unactivated FVIII molecules secreted into the
plasma (Fig. 1). The newly secreted FVIII is a
heterodimer linked by a divalent metal ion. Its
constituents are an 80 kDa light chain composed
of the A3-C1-C2 domains and a heterogeneous
90–210 kDa heavy chain of the A1-A2-B domains
[8,30]. Variable lengths of the partially cleaved B
domain arising from limited C-terminal proteolysis
account for the heterogeneity of the heavy chain [32].
An analysis of five currently commercially available
FVIII replacement concentrates revealed that B
domain terminating at Arg1313 was the predominant
form of the heavy chain in both plasma-derived FVIII
(pdFVIII) and full-length recombinant FVIII (rFVIII)
from both CHO or baby hamster kidney cells [33].
Two additional major heavy chain species contained
truncations of the B domain that terminated also at
Ser817 and Lys1115.
Therefore, the predominant form of unactivated
FVIII circulating in the plasma after secretion or
replacement therapy with full-length FVIII still
contains 572 amino acids of the B domain. More-
over, this section of the B domain also retains 15 of
the 19 N-linked glycosylation sites. Since the B
domain contains no site essential for coagulation
once FVIII is activated, it has been commonly
assumed that the substantial portion of the B
domain that remains on the heavy chain of the
circulating unactivated FVIII has no function. Nev-
ertheless, some evidence suggests that the retained
section of the B domain could modulate the
intermolecular interactions of FVIII with various
molecules and substrates during the various stages
of its life span in the plasma.
Immediately after its release into the circulation,
the FVIII heterodimer interacts with its carrier
protein, von Willebrand factor (VWF), to form a
tight non-covalent complex [21]. Unactivated FVIII
is protected from premature clearance or activation
by its association with VWF, and this interaction is
the most important identified determinant of the
survival of FVIII in the circulation. VWF does not
bind to the B domain, but rather to two light-chain
sites in the A3 and C2 domains [5]. The interaction
of FVIII with other molecules such as FIXa and
membrane phospholipids in platelets is blocked by
VWF [4]. Upon proteolytic activation by thrombin,
FVIII achieves a heterotrimeric structure and under-
goes a conformational change rendering it capable of
binding FIXa and FX on activated platelets.
Activation by thrombin FVIII becomes activated
primarily by thrombin (Fig. 1) and participates as a
cofactor for FIXa in the formation of the tenase
complex on the surface of activated platelets. Addi-
tional components of the complex are FX and Ca2+.
Thrombin activates FVIII by proteolysis at three
residues: Arg372, Arg740 and Arg1689. Arg372 and
Arg1689 are known to be essential sites for FVIII
activation (Fig. 1) [34]. Cleavage at Arg372 bisects
the A1 and A2 domains and at Arg1689 the acidic a3
region from the light chain to create the FVIIIa
heterodimer (A1-a1/ A2-a2/ A3-C1-C2). The ramifi-
cations of proteolysis at Arg740, the boundary
between the A2 and B domains, have not been as
rigorously examined. According to the findings of a
recent study, however, thrombin may act in an
ordered sequence to accomplish cleavage of FVIII
first at Arg740, which then facilitates cleavages at
Arg372 and Arg1689 (Fig. 1) [35]. A number of studies
of BDD-rFVIII have indicated altered patterns of
thrombin activation, possibly caused by a modified
context of the Arg740 thrombin cleavage site [8–11].
In contrast, other studies could not detect any
differences in thrombin activation between BDD-
rFVIII and plasma-derived FVIII (pdFVIII) [36,37].
Moreover, removing approx. 50% of total pdFVIII
carbohydrate did not significantly affect thrombin
potentiation of clotting activity [38].
Platelet binding The formation of the tenase com-
plex requires the delivery of FVIII to the activated
lipid surface of platelets by VWF [12]. The transfer
from VWF to platelets and the tenase complex is a
complicated, multistep process [39]. Unactivated
FVIII does not normally bind to activated platelets
in the presence of VWF. However, in the absence
of VWF, unactivated FVIII can bind to platelets
activated by thrombin, epinephrine or thrombin
receptor peptide with a dissociation constant (Kd) of
10.4 nm [12]. The binding affinity of unactivated
BDD-rFVIII was found to be increased by two
fold, as reflected by a decline in Kd to 5.1 nm. Once
full-length FVIII is activated with thrombin, the
binding affinity to activated platelets increases even
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more (Kd 1.7 nm). Thus, these findings suggest that
the B domain may, like VWF, serve as a brake on
binding of unactivated FVIII to activated platelets,
although the magnitude of this putative modulatory
effect is apparently small compared with that of
VWF.
Inactivation FVIIIa cofactor activity is rapidly lost
either through spontaneous dissociation of the A2
subunit from the rest of the molecule or through
proteolytic degradation by a number of enzymes,
such as thrombin, FIXa, FXa and activated protein C
(aPC). The main physiological inactivator of FVIIIa,
aPC (Fig. 1), cleaves FVIIIa in the A1 (Arg336) and
A2 domains (Arg562). FXa proteolytically inactivates
FVIIIa by cleaving the A1 domain at Lys36 and
Arg336. In a comparison of full-length FVIII and
BDD-rFVIII, proteolysis of A1 and A2 domains of
activated BDD-rFVIII was found to proceed 11–13
times faster than that of activated pdFVIII or full-
length rFVIII [20]. Inactivation of activated BDD-
rFVIII was two to three times faster by aPC and five
to six times by FXa. Accelerated inactivation of
BDD-rFVIII, as well as accelerated activation by
thrombin, would necessitate either higher doses or
more frequent dosing. A 2003 meta-analysis did dem-
onstrate increased bleeding incidence associated with
the use of BDD-rFVIII compared with full-length
FVIII for prophylaxis [40].
Since the last portion of the B domain is cleaved at
the time FVIII is activated, it is unclear why the
BDD-rFVIII should be more vulnerable to proteolysis
than full-length FVIII. Even so, both rFVIII and
pdFVIII displayed comparable rates of proteolysis,
and the suggestion remains that the initial absence of
B domain may render BDD-rFVIII more susceptible
to proteolysis. The investigators ruled out the pos-
sibility that the free B domain can inhibit the action
of aPC and FXa. Thus, addition of purified B domain
to the BDD-rFVIII reaction mixture, even at the same
molar concentration as FVIII, did not decrease the
cleavage rate. Further studies are needed to confirm
and clarify this paradoxical observation.
Clearance An aspect of the residence of FVIII in the
plasma that is very little understood is the clearance
of either the unactivated circulating FVIII molecule
or its breakdown subunits resulting from activation
[4]. Evidence suggests that the N-linked oligosaccha-
ride structures of the B domain may play a role in the
catabolism of FVIII [17]. Low-density lipoprotein
receptor-related protein (LRP), an endocytic recep-
tor, has been found to contribute to the clearance of
FVIII from the circulation [41,42]. Experimental
evidence suggests that other pathways play a role as
well [43]. A potential candidate is the asialoglyco-
protein receptor (ASGPR), a member of the C-type
family of lectins abundantly expressed in the liver
and involved in the binding and endocytic uptake of
glycoproteins from the circulation. The B domain has
been found to bind with high affinity (Kd  2 nm) to
ASGPR, and evidence suggests that the N-linked
oligosaccharides are responsible [17]. Both the intact
FVIII heterodimer and the FVIII heavy chain, but not
the light chain, exhibited similar high-affinity
binding. Treatment with an enzyme that removed
the N-linked oligosaccharide branches abolished the
binding to ASGPR. Finally, BDD-rFVIII was unable
to bind ASGPR. The oligosaccharides on the FVIII
molecule responsible for the high-affinity interaction
with ASGPR remain unknown. Moreover, the phys-
iological significance of the binding is unknown. The
investigators proposed that ASGPR may play a
physiological role in the QC of FVIII biosynthesis
by binding and internalizing incompletely glycosy-
lated FVIII following secretion [17].
Circulating FVIII levels The FVIII levels in normal
persons and half-lives of replacement concentrates
in patients with haemophilia are both characterized
by substantial intraindividual variation. While
some explanatory factors, such as ABO blood
group, have been identified, the reasons for this
variability are still poorly understood. A meta-
analysis of 27 pharmacokinetic studies suggested
that BDD-rFVIII may have a shorter circulating
half-life than full-length FVIII [40]. An acknowl-
edged limitation of the meta-analysis was the
scarcity of available data derived from direct
comparison between FVIII types in the same study.
Two subsequent controlled pharmacokinetic studies
have failed to confirm a half-life difference between
a reformulated BDD-rFVIII preparation and full-
length FVIII [44,45]. Pharmacodynamic differences
between the two FVIII types that may affect
plasma FVIII levels, as suggested by the recent
reports on FVIII activation and clearance, still have
not been adequately explored.
Differences in BDD-rFVIII and full-length FVIII
have been observed in the results obtained from
one-stage clotting assays and chromogenic assays
measuring FVIII levels. This assay discrepancy
between the two methods occurs in vitro as well
as ex vivo after analysis of plasma from treated
patients, and while still unexplained likely reflects
biochemical differences, possibly at least in part
reflecting conformational changes. BDD-rFVIII
activity, as assessed with commercial activated
B DOMAIN OF FACTOR VIII 1193
 2009 Blackwell Publishing Ltd Haemophilia (2009), 15, 1187–1196
partial thromboplastin time (aPTT) reagents, is
consistently about 50% lower than that measured
by the chromogenic assay [46,47]. BDD-rFVIII
displays greater sensitivity than full-length FVIII
to variations in the composition and concentration
of phospholipid [48]. The discrepancy between
assays can be abolished by using mixtures of
source phospholipid in which the content of
phosphatidylserine is maintained below 10% [46].
Interaction of FVIII with phospholipid-containing
membranes is critical for the proper function of the
tenase complex. The lipid binding region of FVIII
resides within the C2 domain (amino acids 2303–
2332) of the molecule [49], and perhaps a subtle
conformational change resulting from the B
domain deletion affects phospholipid binding. The
potency estimation of BDD-rFVIII also appears to
be sensitive to FX activation time in the chromo-
genic method, and there have been discrepancies
even between different chromogenic assay kits [50].
The authors postulated that differences in the
profile of FVIII activation by thrombin may con-
tribute to the discrepancy between BDD-rFVIII and
full-length FVIII in results from the two types of
assays [50]. In 2003, the assay discrepancies
encountered with BDD-rFVIII led to a reformula-
tion of the product with 20% more drug product
than the original formulation in order to achieve
the stated potency [51,52].
It would also be interesting to determine if and
how the B domain affects circulating FVIII levels in
the normal population. Individuals with elevated
FVIII levels have an increased risk for both venous
and arterial thrombosis [53–55]. In a recent study
investigating the influence of FVIII polymorphisms
on plasma FVIII activity levels, the only single-
nucleotide polymorphism (SNP) identified was lo-
cated in the B domain [56]. The SNP was associated
with a substantial increase in FVIII activity. Whether
this polymorphism affects the intracellular traffick-
ing of FVIII or its interactions in the plasma remains
to be determined. Furthermore, while most evidence
suggests that the N-linked glycosylation of the B
domain accounts for much of its actions and char-
acteristics, the role of its protein component remains
unknown. However, a pilot study screening for
protein interactions of the FVIII B domain with liver
proteins identified several interactions with potential
functional implications [57].
Conclusions
Even though it constitutes approx. 40% of the FVIII
molecule, the functions of the B domain have not
been well characterized. While the strongest evi-
dence of its role is in the intracellular trafficking of
FVIII, other intriguing findings and observations
also suggest that it may play a modulatory role in
the plasma.
Nonetheless, consistent evidence has not emerged
to date for a major influence by the B domain on
the fate of FVIII in circulation. A possibly subtle
modulatory role, on the other hand, is suggested by
the above summarized data pertaining to interac-
tions of FVIII with other key elements involved in
the tenase complex or modulations of FVIII levels
in the circulation. Just before FVIII is secreted,
some of the N-linked B domain oligosaccharides
undergo further modification to bi-, tri-, and tetra-
antennary complex-type sugar chains in the Golgi.
The purpose served by these modifications is yet to
be clarified and deserves investigation. It could be
hypothesized that these pre-secretion oligosaccha-
ride modifications might also affect the fate of
FVIII in plasma.
Beyond its relevance to replacement therapy for
haemophilia A, understanding the range of functions
served by the B domain may lead to improved gene
therapy constructs. Most gene therapy applications
for haemophilia A have relied on BDD-rFVIII due to
its advantages of reduced overall cDNA size for
packaging into viral vectors and increased mRNA
levels. However, in vivo results have remained
disappointing, with plasma levels typically undetect-
able (<1%) or in the 1–4% range in a few patients
transiently [16]. Incorporating key B domain
sequences in the constructs may improve the level
of secretion.
Considerable progress continues to be made in
unravelling the complex interaction between cells and
molecules involved in maintaining the balance needed
for effective haemostasis. However, many details of
how this fine balance is achieved still remain undis-
covered or underappreciated. The full story of the B
domain of FVIII is unlikely to have yet been told or its
utility fully exploited.
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